Better Therapeutics to Participate in Chardan’s Virtual Prescription Digital Therapeutics Summit
April 04 2022 - 4:05PM
Business Wire
Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital
therapeutics (PDT) company developing nutritional cognitive
behavioral therapy (nCBT) to address the root causes of
cardiometabolic diseases, today announced that Kevin Appelbaum,
Co-Founder and CEO, will participate in a fireside chat at
Chardan's Virtual Prescription Digital Therapeutics Summit on
Monday, April 11, 2022 at 1:30 p.m. Eastern Time.
A live webcast will be available on the Presentations and Events
section on the Better Therapeutics investor site for approximately
90 days after the event.
About Better Therapeutics
Better Therapeutics is a prescription digital therapeutics (PDT)
company developing a novel form of cognitive behavioral therapy to
address the root causes of cardiometabolic diseases. The company
has developed a proprietary platform for the development of
FDA-regulated, software-based solutions for type 2 diabetes, heart
disease and other conditions. The cognitive behavioral therapy
delivered by Better Therapeutics’ PDT is designed to enable changes
in neural pathways of the brain so lasting changes in behavior
become possible. Addressing the underlying causes of these diseases
has the potential to dramatically improve patient health while
lowering healthcare costs. Better Therapeutics clinically validated
mobile applications are intended to be prescribed by physicians and
reimbursed like traditional medicines.
For more information visit: bettertx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220404005846/en/
Investor Relations: Mark Heinen IR@bettertx.com
Media: Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Better Therapeutics (NASDAQ:BTTX)
Historical Stock Chart
From Jul 2023 to Jul 2024